Autolus Therapeutics plc (AUTL): Operating Income
-$270.54M
Year ended 2025-12-31
-$247.44M
Trailing 12 months to 2026-06-30
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$270.54M | n/m | 2026-03-27, From 2025-01-01 |
| 2024-12-31 | -$241.43M | n/m | 2026-03-27, From 2024-01-01 |
| 2023-12-31 | -$179.70M | n/m | 2025-03-20, From 2023-01-01 |
| 2022-12-31 | -$143.41M | n/m | 2024-03-21, From 2022-01-01 |
| 2021-12-31 | -$141.05M | n/c | 2024-03-21, From 2021-01-01 |
| 2020-12-31 | -$168.15M | n/m | 2023-03-07, From 2020-01-01 |
| 2019-12-31 | -$146.06M | n/a | 2022-03-10, From 2019-01-01 |
| No annual figure between 2018-09-30 and 2019-12-31. | |||
| 2018-09-30 | -$57.53M | n/m | 2020-03-03, From 2017-10-01 |
| 2017-09-30 | -$23.42M | n/a | 2020-03-03, From 2016-10-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| Autolus Therapeutics plc (AUTL) | 2025-12-31 | -$270.54M | n/m |
| Recursion Pharmaceuticals, Inc. (RXRX) | 2025-12-31 | -$648.13M | n/m |
| Compugen Ltd (CGEN) | 2025-12-31 | $31.33M | n/m |
| Black Diamond Therapeutics, Inc. (BDTX) | 2025-12-31 | $12.52M | n/m |
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | -$105.97M | n/m |
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | -$479.33M | n/m |
| 4D Molecular Therapeutics, Inc. (FDMT) | 2025-12-31 | -$159.55M | n/m |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | -$1.14M | n/m |
| Sutro Biopharma, Inc. (STRO) | 2025-12-31 | -$158.37M | n/m |
Compare AUTL, RXRX, CGEN, BDTX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗